A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

DOI record: { "DOI": "10.1038/s41467-020-19056-6", "ISSN": [ "2041-1723" ], "URL": "http://dx.doi.org/10.1038/s41467-020-19056-6", "abstract": "<jats:title>Abstract</jats:title><jats:p>Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.</jats:p>", "alternative-id": [ "19056" ], "article-number": "5284", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "12 July 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "25 September 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "20 October 2020" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-5994-9304", "affiliation": [], "authenticated-orcid": false, "family": "Lyngbakken", "given": "Magnus Nakrem", "sequence": "first" }, { "affiliation": [], "family": "Berdal", "given": "Jan-Erik", "sequence": "additional" }, { "affiliation": [], "family": "Eskesen", "given": "Arne", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6410-2530", "affiliation": [], "authenticated-orcid": false, "family": "Kvale", "given": "Dag", "sequence": "additional" }, { "affiliation": [], "family": "Olsen", "given": "Inge Christoffer", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3720-4659", "affiliation": [], "authenticated-orcid": false, "family": "Rueegg", "given": "Corina Silvia", "sequence": "additional" }, { "affiliation": [], "family": "Rangberg", "given": "Anbjørg", "sequence": "additional" }, { "affiliation": [], "family": "Jonassen", "given": "Christine Monceyron", "sequence": "additional" }, { "affiliation": [], "family": "Omland", "given": "Torbjørn", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2114-3134", "affiliation": [], "authenticated-orcid": false, "family": "Røsjø", "given": "Helge", "sequence": "additional" }, { "affiliation": [], "family": "Dalgard", "given": "Olav", "sequence": "additional" } ], "container-title": "Nature Communications", "container-title-short": "Nat Commun", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 10, 20 ] ], "date-time": "2020-10-20T10:03:16Z", "timestamp": 1603188196000 }, "deposited": { "date-parts": [ [ 2022, 12, 6 ] ], "date-time": "2022-12-06T01:23:10Z", "timestamp": 1670289790000 }, "indexed": { "date-parts": [ [ 2024, 3, 29 ] ], "date-time": "2024-03-29T15:53:45Z", "timestamp": 1711727625334 }, "is-referenced-by-count": 58, "issue": "1", "issued": { "date-parts": [ [ 2020, 10, 20 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2020, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 20 ] ], "date-time": "2020-10-20T00:00:00Z", "timestamp": 1603152000000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 20 ] ], "date-time": "2020-10-20T00:00:00Z", "timestamp": 1603152000000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41467-020-19056-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41467-020-19056-6", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41467-020-19056-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2020, 10, 20 ] ] }, "published-online": { "date-parts": [ [ 2020, 10, 20 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1038/s41422-020-0282-0", "author": "M Wang", "doi-asserted-by": "publisher", "first-page": "269", "journal-title": "Cell Res.", "key": "19056_CR1", "unstructured": "Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).", "volume": "30", "year": "2020" }, { "DOI": "10.1136/bmj.m1849", "author": "W Tang", "doi-asserted-by": "publisher", "first-page": "m1849", "journal-title": "BMJ", "key": "19056_CR2", "unstructured": "Tang, W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369, m1849 (2020).", "volume": "369", "year": "2020" }, { "DOI": "10.1086/652498", "author": "MG Ison", "doi-asserted-by": "publisher", "first-page": "1654", "journal-title": "J. Infect. Dis.", "key": "19056_CR3", "unstructured": "Ison, M. G. et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J. Infect. Dis. 201, 1654–1662 (2010).", "volume": "201", "year": "2010" }, { "DOI": "10.1007/s004020100347", "author": "M Bhandari", "doi-asserted-by": "publisher", "first-page": "96", "journal-title": "Arch. Orthop. Trauma Surg.", "key": "19056_CR4", "unstructured": "Bhandari, M., Lochner, H. & Tornetta, P. 3rd Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Arch. Orthop. Trauma Surg. 122, 96–98 (2002).", "volume": "122", "year": "2002" }, { "key": "19056_CR5", "unstructured": "Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed 22 June 2020." }, { "key": "19056_CR6", "unstructured": "Recovery Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19—preliminary report. N. Engl. J. Med. In press (2020)." }, { "DOI": "10.1001/jama.2020.4783", "author": "C Shen", "doi-asserted-by": "publisher", "first-page": "1582", "journal-title": "JAMA", "key": "19056_CR7", "unstructured": "Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323, 1582–1589 (2020).", "volume": "323", "year": "2020" }, { "DOI": "10.1001/jama.2020.10245", "author": "M Marovich", "doi-asserted-by": "publisher", "first-page": "131", "journal-title": "JAMA", "key": "19056_CR8", "unstructured": "Marovich, M., Mascola, J. R. & Cohen, M. S. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 324, 131–132 (2020).", "volume": "324", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001282", "author": "B Cao", "doi-asserted-by": "publisher", "first-page": "1787", "journal-title": "N. Engl. J. Med.", "key": "19056_CR9", "unstructured": "Cao, B. et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787–1799 (2020).", "volume": "382", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "author": "Y Wang", "doi-asserted-by": "publisher", "first-page": "1569", "journal-title": "Lancet", "key": "19056_CR10", "unstructured": "Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).", "volume": "395", "year": "2020" }, { "key": "19056_CR11", "unstructured": "Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. In press (2020)." }, { "DOI": "10.1016/j.ijid.2020.06.099", "author": "S Arshad", "doi-asserted-by": "publisher", "first-page": "396", "journal-title": "Int. J. Infect. Dis.", "key": "19056_CR12", "unstructured": "Arshad, S. et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int. J. Infect. Dis. 97, 396–403 (2020).", "volume": "97", "year": "2020" }, { "DOI": "10.1101/2020.04.16.20065920", "doi-asserted-by": "crossref", "key": "19056_CR13", "unstructured": "Magagnoli, J. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med In press (2020)." }, { "DOI": "10.1038/s41586-020-2196-x", "author": "R Wolfel", "doi-asserted-by": "publisher", "first-page": "465", "journal-title": "Nature", "key": "19056_CR14", "unstructured": "Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).", "volume": "581", "year": "2020" }, { "DOI": "10.1186/s13063-020-04420-0", "author": "MN Lyngbakken", "doi-asserted-by": "publisher", "journal-title": "Trials", "key": "19056_CR15", "unstructured": "Lyngbakken, M. N. et al. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: a structured summary of a study protocol for a randomised controlled trial. Trials 21, 485 (2020).", "volume": "21", "year": "2020" }, { "key": "19056_CR16", "unstructured": "Royal College of Physicians. National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2. Accessed 1 April 2020." }, { "author": "VM Corman", "first-page": "2000045", "journal-title": "Eur. Surveill.", "key": "19056_CR17", "unstructured": "Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur. Surveill. 25, 2000045 (2020).", "volume": "25", "year": "2020" }, { "DOI": "10.1126/science.2999980", "author": "RK Saiki", "doi-asserted-by": "publisher", "first-page": "1350", "journal-title": "Science", "key": "19056_CR18", "unstructured": "Saiki, R. K. et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354 (1985).", "volume": "230", "year": "1985" } ], "reference-count": 18, "references-count": 18, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41467-020-19056-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Physics and Astronomy", "General Biochemistry, Genetics and Molecular Biology", "General Chemistry", "Multidisciplinary" ], "subtitle": [], "title": "A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "11" }